CEL-SCI Corporation — Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2023. CEL-SCI is a clinical-stage biotechnology company with no approved products and no product sales. Its principal programs are Multikine, an investigational treatment for certain head and neck cancers, and preclinical LEAPS candidates for rheumatoid arthritis.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development | $22.47 million | $25.36 million |
| General and administrative | $9.00 million | $10.71 million |
| Operating loss | $31.48 million | $36.06 million |
| Net loss | $32.19 million | $36.70 million |
| Net loss available to common shareholders | $32.37 million | $37.63 million |
| Basic and diluted loss per share | $0.73 | $0.87 |
| Net cash used in operating activities | $22.85 million | $18.24 million |
R&D fell about 11%, mainly from lower stock-based compensation and Phase III trial costs, partly offset by increased preparation for potential commercial production. G&A fell about 16%, primarily due to lower stock-based compensation. CEL-SCI reported no meaningful revenue base, so profit margins are not applicable. The FY2023 operating loss included approximately $6.3 million of employee equity compensation and $4.0 million of depreciation and amortization.
- Cash and liquidity: Cash and cash equivalents were $4.15 million at September 30, 2023, down from $22.67 million a year earlier. Current assets were $6.92 million and current liabilities $5.59 million.
- Cash use and financing: Cash declined $18.53 million during FY2023. Operating activities used $22.85 million; the company also deposited approximately $2.3 million with its manufacturing-facility landlord after falling below the lease’s required cash threshold. Common-stock sales generated $6.55 million gross and warrant exercises $0.45 million; stock issuance costs were approximately $0.74 million.
- Debt and lease obligations: The balance sheet reports finance lease liabilities of $11.72 million and operating lease liabilities of $1.85 million, approximately $13.57 million combined. These are lease obligations; the filing does not identify conventional borrowing as a significant balance-sheet debt category. The manufacturing-facility lease requires substantial ongoing payments.
- Equity and dilution: 47.42 million shares were outstanding at fiscal year-end; 49.98 million were reported outstanding as of December 8, 2023. Outstanding options and warrants create additional potential dilution.
Material changes and business developments
- CEL-SCI’s Phase III Multikine trial enrolled 928 patients, reached its primary endpoint in April 2020, and was unblinded in June 2021. The company acknowledges that the trial’s primary endpoint—a 10% survival benefit in the overall study population—was not met.
- CEL-SCI reports a later-defined target-population analysis—patients with N0 nodal status, no extracapsular spread, and low PD-L1 expression (TPS below 10%)—showing five-year overall survival of 73% with Multikine versus 45% in controls, with a reported hazard ratio of 0.349. The filing says efficacy in this selected population has not been tested prospectively; these results should not be treated as established or regulator-accepted efficacy.
- FY2023 operating expenses and net loss decreased versus FY2022, but operating cash use increased. Cash fell sharply, and the company relied on equity financing.
- The company said manufacturing-facility commissioning was substantially complete in October 2023. A commercial launch remains contingent on regulatory approval, facility validation and other requirements.
- After year-end, CEL-SCI sold 2.49 million shares in November 2023 for approximately $4.5 million in net proceeds.
Outlook, risks and unusual items
- Regulatory plans: Management intends to pursue conditional or accelerated approval for Multikine, prioritizing Europe and the UK, and has requested Scientific Advice meetings anticipated in the first half of 2024. CEL-SCI planned to provide new data to the FDA and Health Canada in Q1 2024. In the U.S., it said a confirmatory trial would need to be underway before accelerated approval; no assurance is given that any regulator will accept the data or approve the product.
- Funding and going concern: The auditor and management state that recurring losses and future liquidity needs raise substantial doubt about CEL-SCI’s ability to continue as a going concern. The company expects to need additional capital through equity, debt, partnerships or other financing; availability and terms are uncertain. Funding shortfalls could delay or curtail development.
- Development and commercialization: Multikine remains investigational and is not approved; LEAPS candidates have not entered human clinical trials. The company has no established definitive marketing plan, pricing structure, or sales force. Reimbursement, market acceptance, manufacturing scale-up, regulatory review and additional trial requirements are material uncertainties.
- Costs and commitments: CEL-SCI estimates approximately $0.7 million in remaining Phase III-related and clinical study report costs, based on CRO information; this excludes other related costs, including potential manufacturing costs. The long-term manufacturing lease and associated payments remain significant commitments.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at September 30, 2023. Material weaknesses involved IT logical-access controls and certain management review controls. Management reported no resulting material financial-statement misstatement and described remediation efforts. The external auditor did not audit internal control effectiveness.
- Other risks: The filing highlights potential future dilution, stock-price volatility, dependence on Multikine, competition, product liability, intellectual-property protection, and evolving regulatory and reimbursement requirements. No legal proceedings were reported as applicable in Item 3.
Important facts for investors to verify
- Whether regulators view the selected Multikine target-population analysis as adequate despite the missed overall Phase III primary endpoint and the absence of prospective testing in that population.
- Cash runway, the timing and terms of additional financing, and whether subsequent share issuance materially dilutes existing shareholders.
- Progress and results of regulatory consultations, the confirmatory-trial plan, and any formal applications or decisions.
- Completion of manufacturing validation and readiness for regulatory inspection and commercial-scale production.
- Remediation and independent confirmation of the disclosed internal-control material weaknesses.
- Actual remaining trial, regulatory, manufacturing and lease-related costs, including costs not covered by the company’s approximately $0.7 million estimate.